Bli medlem
Bli medlem

Du är här

2016-11-11

Active Biotech: Active Biotech AB Interim report January - September 2016

Laquinimod

* The clinical trials CONCERTO, ARPEGGIO and LEGATO-HD are progressing
according to plan
* The study results from the pivotal clinical Phase 3 CONCERTO trial in
relapsing remitting multiple sclerosis (RRMS) are expected in the first
half of 2017
* The study results from the pivotal clinical Phase 2 ARPEGGIO study,
evaluating laquinimod for the treatment of primary progressive multiple
sclerosis (PPMS), are expected in the second half of 2017
* Preclinical results concerning laquinimod were presented at the ECTRIMS
2016 Congress held in London, UK, on September 14-17, 2016
* Special Protocol Assessment (SPA) for laquinimod rescinded after
discussions with the FDA

ANYARA

* Licensing agreement entered into with NeoTX Therapeutics Ltd

Tasquinimod, Paquinimod (57-57) and SILC (ISI)

* Out-licensing activities are continuing

New share issue

* The Board of Directors has today decided, based on the authorization
granted by the Annual General Meeting, to implement a rights issue totaling
approximately SEK 55 M
* The issue is at no cost guaranteed in full by the company's largest owner
MGA Holding AB

Financial summary

---------------------------------------------------------------------------------------------
| SEK M July - Sept Jan - Sept Full Year |
| 2016 2015 2016 2015 2015 |
| |
| Net sales 4.1 5.2 12.0 11.3 16.3 |
| Operating loss -11.1 -22.2 -41.6 -149.7 -177.9 |
| Loss for the period -12.4 -23.4 -44.8 -152.7 -193.5 |
| Loss per share, before and after dilution (SEK) -0.14 -0.26 -0.50 -1.70 -2.15 |
| Cash and cash equivalents (at the end of the period) 39.9 132.4 103.6 |
---------------------------------------------------------------------------------------------
* Operating costs reduced by 67 % (SEK 107.4 M) compared with 2015
* Operations are progressing according to plan pending the Phase 3 results
for laquinimod in the first half of 2017

For further information, please contact:

--------------------------------------------------------------------
| Tomas Leanderson, President and CEO Active Biotech AB |
| Tel: +46 46 19 20 95 |
| (Corp. Reg. No. 556223-9227) |
| Box 724, SE-220 07 Lund |
| Tel: +46 46 19 20 00 |
| Hans Kolam, CFO Fax: +46 46 19 11 05 |
| Tel: +46 46 19 20 44 |
--------------------------------------------------------------------
The report is also available atwww.activebiotech.com.

Active Biotech AB Interim Report Jan-Sept 2016
http://hugin.info/1002/R/2056455/770255.pdf

---------------------------------------
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Active Biotech via Globenewswire

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.